We are live on ! Find out more
ZVSA icon

ZyVersa Therapeutics
ZVSA

Delisted

ZVSA was delisted on the 16th of July, 2025.

Back to rankings

8 hedge funds and large institutions have $86.2K invested in ZyVersa Therapeutics in 2024 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

6,159,750% more capital inflows, than outflows

Capital inflows: $123K | Capital outflows: $2

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

33% more funds holding

Funds holding: 6 → 8 (+2)

3.1% more ownership

Funds ownership: 0.13% → 3.23% (+3.1%)

Holders
8
Holders Change
+2
Holders Change %
+33.33%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
3
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citigroup
Citigroup
New York
+$55.3K
2
VF
Virtu Financial
New York
+$39.9K
3
Renaissance Technologies
Renaissance Technologies
New York
+$20.5K
4
UBS Group
UBS Group
Switzerland
+$5.92K
5
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
+$1.45K

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$2

ZVSA Hedge Fund Activity: Q4 2024 in Review

8 of the 7,614 institutional investors tracked by Wall St. Rank reported a position in ZyVersa Therapeutics (ZVSA) for Q4 2024, worth a combined $86.2K — up 1,094% from $7.22K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new ZVSA positions and 2 closed out — a net gain of 2 holders — while 3 added to existing stakes and 0 trimmed.

The largest buyer was Citigroup, opening a new position worth an estimated $55.3K. The largest seller was JP Morgan Chase, exiting entirely with an estimated $2 sold.

  • 8 institutional investors held ZyVersa Therapeutics (ZVSA) as of Q4 2024, up from 6 in Q3 2024.
  • Funds reported $86.2K of ZyVersa Therapeutics stock for Q4 2024, up 1,094% quarter-over-quarter.
  • 4 funds opened new ZyVersa Therapeutics positions in Q4 2024 and 2 closed out, a net change of +2 holders.
  • The largest ZyVersa Therapeutics buyer in Q4 2024 was Citigroup, an estimated $55.3K added.
  • The largest ZyVersa Therapeutics seller in Q4 2024 was JP Morgan Chase, an estimated $2 sold.

Based on aggregated 13F filings for Q4 2024.